Nanoparticles as carrier for improve therapeutic efficacy of pioglitazone in ocular inflammatory disorders: development and validation of a high throughput LC-MS/MS method for quantitation in ocular tissues

Abstract: Pioglitazone is an oral anti-hyperglycemic agent and it is used for the treatment of diabetes mellitus type 2. The anti-inflammatory activity has also been demonstrated in the literature. Pioglitazone belongs to Class II of Biopharmaceutical Classification System, i.e., slightly soluble an...

ver descrição completa

Detalhes bibliográficos
Autores: Miralles, Esther, Silva Abreu, Marcelle, Calpena Campmany, Ana Cristina, Casals, Isidre
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Recursos:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/183775
Acesso em linha:https://hdl.handle.net/2445/183775
Access Level:acceso abierto
Palavra-chave:Nanopartícules
Farmacologia ocular
Sistemes d'alliberament de medicaments
Agents antiinflamatoris
Nanoparticles
Ocular pharmacology
Drug delivery systems
Antiinflammatory agents
id ES_9ed377856808eb7f706edda7a968ca2b
oai_identifier_str oai:diposit.ub.edu:2445/183775
network_acronym_str ES
network_name_str España
repository_id_str
spelling Nanoparticles as carrier for improve therapeutic efficacy of pioglitazone in ocular inflammatory disorders: development and validation of a high throughput LC-MS/MS method for quantitation in ocular tissuesMiralles, EstherSilva Abreu, MarcelleCalpena Campmany, Ana CristinaCasals, IsidreNanopartículesFarmacologia ocularSistemes d'alliberament de medicamentsAgents antiinflamatorisNanoparticlesOcular pharmacologyDrug delivery systemsAntiinflammatory agentsAbstract: Pioglitazone is an oral anti-hyperglycemic agent and it is used for the treatment of diabetes mellitus type 2. The anti-inflammatory activity has also been demonstrated in the literature. Pioglitazone belongs to Class II of Biopharmaceutical Classification System, i.e., slightly soluble and highly permeable. Polymeric nanoparticle formulations play an important role in the improvement of the efficacy of ocular therapies. These systems are non-toxic and biodegradable, show appropriate physicochemical characteristics as well as prolonged release profile suitable for ocular delivery. An accurate, sensitive, selective, reproducible and high throughput HPLC-MS/MS method was validated to quantitate pioglitazone in ocular tissues (cornea, sclera, lens, aqueous humour and vitreous humour). The chromatographic separation was achieved in 10 min on a Kinetex C18 column. Linear response of pioglitazone was observed over the range of 5-100 ng/ml. The limit of quantitation was 10 ng/ml (in extract). The recovery of pioglitazone or pioglitazone encapsulated in nanoparticles of polylactic-co-glycolic acid-polyethylene glycol (PLGA-PEG) was in the range 85-115 % in all tissues and levels tested. The intra-day and inter-day precision were <5 % and <10 % respectively. The obtained extracts demonstrated to be stable under various experimental conditions in all the studied matrices. This method can be applied to in vivo and ex vivo biodistribution studies related to the ocular administration of pioglitazone nanoparticles.MDPI2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/183775Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics13050650MDPI Proceedings, 2020, vol. 2021, num. 13, p. 650https://doi.org/10.3390/pharmaceutics13050650cc-by (c) Miralles, Esther et al., 2020https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1837752026-05-27T06:46:51Z
dc.title.none.fl_str_mv Nanoparticles as carrier for improve therapeutic efficacy of pioglitazone in ocular inflammatory disorders: development and validation of a high throughput LC-MS/MS method for quantitation in ocular tissues
title Nanoparticles as carrier for improve therapeutic efficacy of pioglitazone in ocular inflammatory disorders: development and validation of a high throughput LC-MS/MS method for quantitation in ocular tissues
spellingShingle Nanoparticles as carrier for improve therapeutic efficacy of pioglitazone in ocular inflammatory disorders: development and validation of a high throughput LC-MS/MS method for quantitation in ocular tissues
Miralles, Esther
Nanopartícules
Farmacologia ocular
Sistemes d'alliberament de medicaments
Agents antiinflamatoris
Nanoparticles
Ocular pharmacology
Drug delivery systems
Antiinflammatory agents
title_short Nanoparticles as carrier for improve therapeutic efficacy of pioglitazone in ocular inflammatory disorders: development and validation of a high throughput LC-MS/MS method for quantitation in ocular tissues
title_full Nanoparticles as carrier for improve therapeutic efficacy of pioglitazone in ocular inflammatory disorders: development and validation of a high throughput LC-MS/MS method for quantitation in ocular tissues
title_fullStr Nanoparticles as carrier for improve therapeutic efficacy of pioglitazone in ocular inflammatory disorders: development and validation of a high throughput LC-MS/MS method for quantitation in ocular tissues
title_full_unstemmed Nanoparticles as carrier for improve therapeutic efficacy of pioglitazone in ocular inflammatory disorders: development and validation of a high throughput LC-MS/MS method for quantitation in ocular tissues
title_sort Nanoparticles as carrier for improve therapeutic efficacy of pioglitazone in ocular inflammatory disorders: development and validation of a high throughput LC-MS/MS method for quantitation in ocular tissues
dc.creator.none.fl_str_mv Miralles, Esther
Silva Abreu, Marcelle
Calpena Campmany, Ana Cristina
Casals, Isidre
author Miralles, Esther
author_facet Miralles, Esther
Silva Abreu, Marcelle
Calpena Campmany, Ana Cristina
Casals, Isidre
author_role author
author2 Silva Abreu, Marcelle
Calpena Campmany, Ana Cristina
Casals, Isidre
author2_role author
author
author
dc.subject.none.fl_str_mv Nanopartícules
Farmacologia ocular
Sistemes d'alliberament de medicaments
Agents antiinflamatoris
Nanoparticles
Ocular pharmacology
Drug delivery systems
Antiinflammatory agents
topic Nanopartícules
Farmacologia ocular
Sistemes d'alliberament de medicaments
Agents antiinflamatoris
Nanoparticles
Ocular pharmacology
Drug delivery systems
Antiinflammatory agents
description Abstract: Pioglitazone is an oral anti-hyperglycemic agent and it is used for the treatment of diabetes mellitus type 2. The anti-inflammatory activity has also been demonstrated in the literature. Pioglitazone belongs to Class II of Biopharmaceutical Classification System, i.e., slightly soluble and highly permeable. Polymeric nanoparticle formulations play an important role in the improvement of the efficacy of ocular therapies. These systems are non-toxic and biodegradable, show appropriate physicochemical characteristics as well as prolonged release profile suitable for ocular delivery. An accurate, sensitive, selective, reproducible and high throughput HPLC-MS/MS method was validated to quantitate pioglitazone in ocular tissues (cornea, sclera, lens, aqueous humour and vitreous humour). The chromatographic separation was achieved in 10 min on a Kinetex C18 column. Linear response of pioglitazone was observed over the range of 5-100 ng/ml. The limit of quantitation was 10 ng/ml (in extract). The recovery of pioglitazone or pioglitazone encapsulated in nanoparticles of polylactic-co-glycolic acid-polyethylene glycol (PLGA-PEG) was in the range 85-115 % in all tissues and levels tested. The intra-day and inter-day precision were <5 % and <10 % respectively. The obtained extracts demonstrated to be stable under various experimental conditions in all the studied matrices. This method can be applied to in vivo and ex vivo biodistribution studies related to the ocular administration of pioglitazone nanoparticles.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/183775
url https://hdl.handle.net/2445/183775
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics13050650
MDPI Proceedings, 2020, vol. 2021, num. 13, p. 650
https://doi.org/10.3390/pharmaceutics13050650
dc.rights.none.fl_str_mv cc-by (c) Miralles, Esther et al., 2020
https://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Miralles, Esther et al., 2020
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414859342348288
score 15,301603

Registos relacionados